Use of polymers based on intertwined saccharides as a drug to treat diabetes, obesity and other illnesses
This invention developed by the University of Granada refers to the use of polymers based on intertwined saccharides as a drug for the treatment of conditions that require the hijacking of sterols ad/or bilic acids.
The polymers are obtained from cyclodextrins and/or polysaccharides, such as starch or dextrine, which are intertwined with bis vinyl-sulfones, producing homopolymer and heteropolymer materials. These materials can be used for the treatment of hyperlipidemia, diabetes, arteriosclerosis, hypercholesterolaemia, hypertriglyceridemia, hyperglycaemia and obesity, without being limited to other illnesses that require the elimination of sterols and/or bilic acids.
The in vivo tests carried out have shown an absence of toxicity in the polymers tested. In general, the capacity of these polymers for regulating hypercholesterolaemia is similar to that of the SAB cholestyramine (used as a reference), but with three additional advantages:
- They normalise the level of triglycerides,
- They don’t increase the level of creatinine,
- Some of these compounds reduce the level of glucose in serum.
Companies interested in licensing the technology for its commercial exploitation.
Sectors of application: Pharmacy, Healthcare.
Stage of development: Patent in process. “In vivo” testing.
Priority date: 11/02/2015.
Owner: University of Granada.